CROWN and BRIGHTSTAR Studies: Latest Data Insights
October 25th 2024Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
Read More
Molecular Testing and First-Line Treatment Selection in ALK-Positive NSCLC
October 25th 2024Panelists discuss the importance of molecular testing in NSCLC, particularly for ALK rearrangements, and explore how recent advancements and emerging technologies are shaping first-line treatment selection for ALK-positive patients.
Read More
What is the Role of Molecular Testing in Resectable Non–Small Cell Lung Cancer?
Shared insight from key opinion leaders on the value of molecular testing in patients with resectable non–small cell lung cancer and how it can be applied.
Read More
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
November 14th 2022Balazs Halmos, MD, discusses the importance of testing for HER2 mutations and exon 20 insertions, which are emerging new targets in non–small cell lung cancer, and how fam-trastuzumab deruxtecan-nxki meets needs for patients with HER2-mutant disease.
Read More
Revolutionizing Targeted Therapy With EGFR Exon 20 and the Early-Stage NSCLC Setting
January 7th 2022Josh Sabari, MD; Nicholas C. Rohs, MD; and Balazs Halmos, MD, discuss the updates with targeted therapy as it relates to the early-stage setting of non–small cell lung cancer as well as those who harbor EGFR exon 20 insertion mutations.
Read More
Shaping the Use of Immunotherapy in the Localized Lung Cancer Setting
January 7th 2022Thoracic Night Live is devoted to spotlighting the biggest topics in lung cancer and pivotal studies discussed at medical meetings throughout the year. This episode is a review of the clinical advancements in lung cancer treatment throughout 2021. Funding from Daiichi Sankyo/Content Independently Developed by OncLive
Read More
Early-Stage NSCLC Is Ripe for Change
February 13th 2019Following a 2-decade lull in early-stage lung cancer, we are now seeing much better-designed neoadjuvant and adjuvant studies based on proper biomarker selection, as well as optimized treatment choices founded upon recent advances in the metastatic setting.
Read More
Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer
October 7th 2014Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.
Read More
Dr. Halmos on Checkpoint Inhibitors in Lung Cancer
April 2nd 2014Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the anti-PD-L1 antibody MK-3475 and the challenge of integrating immunotherapies into the field of lung cancer.
Read More